
Opinion|Videos|June 10, 2024
Efficacy and Safety Data from SunRISe-1
The panel reviews data from the SunRISe-1 trial investigating TAR-200 and offers its impressions on the efficacy and safety findings.
Advertisement
Episodes in this series

Advertisement
Latest CME
Advertisement
Advertisement
Trending on Urology Times
1
FDA approves lutetium Lu 177 vipivotide tetraxetan for PSMA-positive mHSPC
2
Individualizing androgen pathway therapy in mCSPC
3
Testosterone deficiency: FAQs from the AUA guideline
4
Cretostimogene Grenadenorepvec: Mechanism and Rationale
5













